NCT04457336Phase 2Terminated

A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-02-09Actual

Enrollment · participants96Actual

Source updated2025-07-08Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Congenital Adrenal Hyperplasia

Treatments or interventions studied

Tildacerfont/PlaceboDrugAlso known as SPR001

Primary outcomes · main study measures

measure: To Evaluate the Effect of Tildacerfont in Reducing A4 in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Over 12 Weeks; description: Assessment of dose response for change from baseline in log A4 after 12 weeks on double-blind placebo-controlled treatment (Week 18); timeFrame: Baseline and 12 weeks of treatment (Week 18)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history